Leonteq Securities AG Buys New Stake in DaVita Inc. $DVA

Leonteq Securities AG bought a new stake in shares of DaVita Inc. (NYSE:DVA) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 2,828 shares of the company’s stock, valued at approximately $321,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Elevation Wealth Partners LLC lifted its holdings in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of DaVita during the 2nd quarter valued at $43,000. iSAM Funds UK Ltd acquired a new position in shares of DaVita during the 3rd quarter valued at $46,000. Stance Capital LLC acquired a new position in shares of DaVita during the 3rd quarter valued at $47,000. Finally, Camelot Portfolios LLC acquired a new position in shares of DaVita during the 4th quarter valued at $57,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Barclays lifted their target price on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and lifted their target price for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. Truist Financial boosted their price objective on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Finally, TD Cowen boosted their price objective on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $199.17.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is owned by corporate insiders.

DaVita Price Performance

Shares of DVA stock opened at $198.39 on Friday. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $202.69. The firm has a market capitalization of $12.74 billion, a P/E ratio of 18.40, a P/E/G ratio of 0.65 and a beta of 0.84. The company’s fifty day moving average price is $162.93 and its two-hundred day moving average price is $138.13.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the previous year, the business posted $2.00 EPS. The firm’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 15.07 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.